

7 November 2018

Australian Securities Exchange
Level 40, Central Park
152-158 St Georges Tce
Perth WA 6000

Via email: tradinghaltspert@asx.com.au

Dear Sir/Madam

MGC Pharmaceuticals Ltd – Voluntary Suspension Extension Request

Pursuant to ASX Listing Rule 17.2, MGC Pharmaceuticals Ltd (ASX: MXC) (the “Company”) requests an extension of the voluntary suspension over the Company’s securities from the commencement of trade on Wednesday, 7 November 2018.

In accordance with ASX Listing Rule 17.2 the Company provides the following information regarding the extension request:

1. The voluntary suspension request by the Company is to allow finalisation of all formal documentation by CannaGlobal relating to the acquisition of MGC Derma, and simultaneous completion of related CannaGlobal transactions including their financing facility and other asset acquisitions.
2. The Company expects the voluntary suspension to end no later than the commencement of trade on Tuesday 13 November 2018, when it anticipates it will be in a position to make a detailed announcement to the market in respect of the abovementioned transaction.
3. The Company is not aware of any reason why the voluntary suspension should not be granted, nor of any other information necessary to inform the market about the voluntary suspension.

On behalf of the Board

[signed electronically without signature]

Kate Sainty

Joint Company Secretary

MGC Pharmaceuticals Ltd